Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 4. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 demonstrates antitumor activity across multiple.

Published byBarrie Clarke Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 4. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 demonstrates antitumor activity across multiple."— Presentation transcript:

1 Fig. 4. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models.
BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 antitumor activity in both primary and refractory KIT-driven disease models. (A to C) Antitumor activity (A), body weight (B), and PK/PD (C) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model. (D to F) Antitumor activity of BLU-285 and reference compounds (top) and pharmacodynamic analysis of KIT inhibition (bottom) in human GIST PDX models of disease with (D) KIT exon 11/17 delW557K558/Y823D, (E) KIT exon 11 delW557-V559insF, and (F) KIT exon 11/13 delW557K558/V654A mutations. QD, once daily; BID, twice daily. Erica K. Evans et al., Sci Transl Med 2017;9:eaao1690 Published by AAAS

Download ppt "Fig. 4. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 demonstrates antitumor activity across multiple."

Similar presentations

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Fig. 7. Intrapatient variation in key contact signatures for PGDM1400 and PGT121. Intrapatient variation in key contact signatures for PGDM1400 and PGT121.

Fig. 7. Intrapatient variation in key contact signatures for PGDM1400 and PGT121. Intrapatient variation in key contact signatures for PGDM1400 and PGT121.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.
Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.
Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.

Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.
Fig. 1. [11C]Martinostat images of all subjects show high cortical binding and distinct gray-white matter differences. [11C]Martinostat images of all subjects.

Fig. 1. [11C]Martinostat images of all subjects show high cortical binding and distinct gray-white matter differences. [11C]Martinostat images of all subjects.
Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. Mutational signature exposures in Taiwan HCCs and summary.

Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. Mutational signature exposures in Taiwan HCCs and summary.
Fig. 3. Structure of ALS-associated RNA binding proteins.

Fig. 3. Structure of ALS-associated RNA binding proteins.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
Fig. 4. Biomechanical properties of treated tibiae.

Fig. 4. Biomechanical properties of treated tibiae.
Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.

Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.
Fig. 1. Schematic representation of the MANO method.

Fig. 1. Schematic representation of the MANO method.
Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 1 Crohn’s disease association within the LRRK2 locus.
Fig. 3. Frequencies of amino acids at critical PGT121 and 10-1074 contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Similar presentations

Ads by Google